Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

by Marisi, Giorgia, Cucchetti, Alessandro, Ulivi, Paola, Canale, Matteo, Cabibbo, Giuseppe, Solaini, Leonardo, Foschi, Francesco G, De Matteis, Serena, Ercolani, Giorgio, Valgiusti, Martina, Frassineti, Giovanni L, Scartozzi, Mario, Casadei Gardini, Andrea
Published in World J Gastroenterol (2018)

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

by Gardini, Andrea Casadei, Scarpi, Emanuela, Faloppi, Luca, Scartozzi, Mario, Silvestris, Nicola, Santini, Daniele, de Stefano, Giorgio, Marisi, Giorgia, Negri, Francesca V., Foschi, Francesco Giuseppe, Valgiusti, Martina, Ercolani, Giorgio, Frassineti, Giovanni Luca
Published in Oncotarget (2016)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy

by Faloppi, Luca, Del Prete, Michela, Gardini, Andrea Casadei, Santini, Daniele, Silvestris, Nicola, Bianconi, Maristella, Giampieri, Riccardo, Valgiusti, Martina, Brunetti, Oronzo, Bittoni, Alessandro, Andrikou, Kalliopi, Lai, Eleonora, Dessì, Alessandra, Cascinu, Stefano, Scartozzi, Mario
Published in Sci Rep (2016)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

by Casadei Gardini, Andrea, Foca, Flavia, Scartozzi, Mario, Silvestris, Nicola, Tamburini, Emiliano, Faloppi, Luca, Brunetti, Oronzo, Rudnas, Britt, Pisconti, Salvatore, Valgiusti, Martina, Marisi, Giorgia, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Tassinari, Davide, Cascinu, Stefano, Frassineti, Giovanni Luca
Published in Sci Rep (2017)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review

by Gardini, Andrea Casadei, Santini, Daniele, Aprile, Giuseppe, Silvestris, Nicola, Felli, Emanuele, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Marisi, Giorgia, Valgiusti, Martina, Passardi, Alessandro, Puzzoni, Marco, Silletta, Marianna, Brunetti, Oronzo, Cardellino, Giovanni Gerardo, Frassineti, Giovanni Luca, Scartozzi, Mario
Published in Oncotarget (2017)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study

by Gardini, Andrea Casadei, Marisi, Giorgia, Faloppi, Luca, Scarpi, Emanuela, Foschi, Francesco Giuseppe, Iavarone, Massimo, Lauletta, Gianfranco, Corbelli, Jody, Valgiusti, Martina, Facchetti, Floriana, Corte, Cristina della, Neri, Luca Maria, Tamberi, Stefano, Cascinu, Stefano, Scartozzi, Mario, Amadori, Dino, Nanni, Oriana, Tenti, Elena, Ulivi, Paola, Frassineti, Giovanni Luca
Published in Oncotarget (2016)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

by Marisi, Giorgia, Petracci, Elisabetta, Raimondi, Francesco, Faloppi, Luca, Foschi, Francesco Giuseppe, Lauletta, Gianfranco, Iavarone, Massimo, Canale, Matteo, Valgiusti, Martina, Neri, Luca Maria, Ulivi, Paola, Orsi, Giulia, Rovesti, Giulia, Vukotic, Ranka, Conti, Fabio, Cucchetti, Alessandro, Ercolani, Giorgio, Andrikou, Kalliopi, Cascinu, Stefano, Scartozzi, Mario, Casadei-Gardini, Andrea
Published in Cancers (Basel) (2019)